Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy

Clinical and Experimental Allergy

Volumn 42, Issue 10, 2012, Pages 1510-1518

  Baron Bodo, V ^a   Batard, T ^a   Nguyen, H ^a   Frereux M ^a   Horiot, S ^a   Harwanegg, C ^b   Bergmann, K C ^c   de Beaumont, O ^a   Moingeon, P ^a  

^a Stallergenes SA   (France)

^b Thermo Fisher Scientific   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Allergen; Antibody; House dust mite; IgE; IgG; Immunotherapy; Neosensitization; Sublingual tablets

Indexed keywords

HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ALLERGIC RHINITIS; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AVERAGE RHINITIS TOTAL SYMPTOM SCORE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CULTURE MEDIUM; DERMATOPHAGOIDES; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; HOUSE DUST ALLERGY; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; IMMUNOSOLID PHASE ALLERGEN CHIP ASSAY; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; NEOSENSITIZATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SENSITIZATION; SUBLINGUAL IMMUNOTHERAPY; SYMPTOM; TABLET; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WHEAT GERM; YEAST;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PYROGLYPHIDAE; RHINITIS, ALLERGIC, PERENNIAL; TABLETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866599075     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2012.04044.x     Document Type: Article

References (39)

1. Canonica GW, Bousquet J, Casale T et al. Sublingual immunotherapy. World Allergy Organization Position Paper. Allergy 2009; 64:1-59.
2. Passalacqua G, Lombardi C, Troise C, Canonica GW. Sublingual immunotherapy: certainties, unmet needs and future directions. Eur Ann Allergy Clin Immunol 2009; 41:163-70.
3. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-40.
4. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-45.
5. 2LEN meta-analysis. Allergy 2009; 64:1570-9.
6. Bergmann KC, Worm M, Fokkens WJ et al. Efficacy and safety of house dust mite allergen extracts tablets in adults with allergic rhinitis. J Allergy Clin Immunol 2010; 125 (Suppl. 1):AB122.
7. Mosbech H. Tolerability and efficacy of house dust mite AIT. Allergy 2011; 66 (suppl 95):55-6.
8. Bousquet J, Scheinmann P, Guinnepain MT et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999; 54:249-60.
9. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000; 55:842-9.
10. Bahçeciler NN, Işik U, Barlan IB, Başaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32:49-55.
11. Fernandez-Caldas E, Iraola V, Boquete M, Nieto A, Casanovas M. Mite immunotherapy. Curr Allergy Asthma Rep 2006; 6:413-9.
12. Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006; 100:1374-83.
13. Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17:408-15.
14. Pham-Thi N, Scheinmann P, Fadel R, Combebias, André C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007; 18:47-57.
15. Sidenius KE, Hallas TE, Brygge T, Poulsen LK, Mosbech H. House dust mites and their allergens at selected locations in the homes of house dust mite-allergic patients. Clin Exp Allergy 2002; 32:1299-304.
16. Pittner G, Vrtala S, Thomas WR et al. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004; 34:597-603.
17. Weghofer M, Thomas WR, Kronqvist M et al. Variability of IgE reactivity profiles among european mite allergic patients. Eur J Clin Invest 2008; 38:959-65.
18. Hales BJ, Martin AC, Pearce LJ et al. IgE and IgG anti-house dust mite specificities in allergic disease. J Allergy Clin Immunol 2006; 118:361-7.
19. Thomas WR. Geography of house dust mite allergens. Asian Pac J Allergy Immunol 2010; 28:211-24.
20. Thomas WR, Hales BJ, Smith WA. House dust mite allergens in asthma and allergy. Trends Mol Med 2010; 16:321-8.
21. Moingeon P, Hrabina M, Bergmann KC et al. Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine. Int Arch Allergy Immunol 2008; 146:338-42.
22. Ball T, Sperr WR, Valent P et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999; 29:2026-36.
23. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002; 57:423-30.
24. Van Ree R, Antonicelli L, Akkerdaas JH, Garritani MS, Aalberse RC, Bonifazi F. Possible induction of food allergy during mite immunotherapy. Allergy 1996; 51:108-13.
25. Aki T, Kodama T, Fujikawa A et al. Immunochemical characteristion of recombinant and native tropomyosins as a new allergen from the house dust mite Dermatophagoides farinae. J Allergy Clin Immunol 1995; 96:74-83.
26. Ayuso R, Reese G, Leong-Kee S, Plante M, Lehrer SB. Molecular basis of arthropod cross-reactivity: IgE-binding cross-reactive epitopes of shrimp, house dust mite and cockroach tropomyosins. Int Arch Allergy Immunol 2002; 129:38-48.
27. Reese G, Ayuso R, Lehrer SB. Tropomyosin: an invertebrate pan-allergen. Int Arch Allergy Immunol 1999; 119:247-58.
28. Resch Y, Weghofer M, Seiberler S et al. Molecular characterization of Der p 10: a diagnostic marker for broad sensitization in house dust mite allergy. Clin Exp Allergy 2011; 41:1467-77.
29. Pajno GB, La Grutta S, Barberio G, Canonica GW, Passalacqua G. Harmful effect of immunotherapy in children with combined snail and mite allergy. J Allergy Clin Immunol. 2002; 109:627-9.
30. Antonicelli L, Mariano M. Mite immunotherapy and food allergy to snail. Allergy 2003; 58:821.
31. Moingeon P, Batard T, Fadel R, Frati F, Sieber H, van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-65.
32. Mascarell L, Lombardi V, Louise A et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008; 122:603-9.
33. Batard T, Hrabina A, Zhi Bi X et al. Production and characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae house dust mites for allergy vaccines. Int Arch Allergy Immunol 2006; 140:295-305.
34. Harwanegg C, Hutter S, Hiller R. Allergen microarrays for the diagnosis of specific IgE against components of cow's milk and hen's egg in a multiplex biochip-based immunoassay. Meth Mol Biol 2007; 385:145-57.
35. Asero R. Lack of de novo sensitization to tropomyosin in a group of mite-allergic patients treated by house dust mite-specific immunotherapy. Int Arch Allergy Immunol 2005; 137:62-5.
36. Rossi R, Monasterolo G, Incorvaia C et al. Lack of neo sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy. Clin Mol Allergy 2010; 8:4-11.
37. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005; 115:1184-8.
38. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.
39. James LK, Shamji MH, Walker SM et al. Long term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127:509-16.